3,4-Methylenedioxy-N-propylamphetamine

MDPR
Clinical data
Routes of
administration		Oral[1]
Drug classPsychoactive drug[1]
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1]
Identifiers
  • N-[1-(2H-1,3-benzodioxol-5-yl)propan-2-yl]propan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.217.125
Chemical and physical data
FormulaC13H19NO2
Molar mass221.300 g·mol−1
3D model (JSmol)
  • CC(NCCC)Cc1ccc2OCOc2c1
  • InChI=1S/C13H19NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h4-5,8,10,14H,3,6-7,9H2,1-2H3
  • Key:LBXMQBTXOLBCCA-UHFFFAOYSA-N
  (verify)

3,4-Methylenedioxy-N-propylamphetamine (MDPR) is a lesser-known psychoactive drug and a substituted amphetamine. MDPR was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 200 mg, and the duration unknown.[1] MDPR is described as a "promoter"; by itself it has almost no effects on the mind, but it promotes the effects of hallucinogens, similarly to the closely related MDPH.[1]

Shulgin reported that 160 mg of MDPR strongly enhanced the effects of a small (60 μg) dose of LSD,[1] and that similar enhancement of hallucinogenic effect was noted when mixing MDPR with other drugs such as psilocybin, mescaline, 2C-B, and 2C-T-7.[1] The reason for this synergistic action of MDPR has not been elucidated.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPR other than what is written in PiHKAL.[1]

See also

References

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.